Insight Molecular Diagnostics Inc. Common Stock
$3.84
$0.26 (+7.26%)
$3.51Day Range$3.86
Key Statistics
Market Cap
$117.15M
Shares Outstanding
32.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 30, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$3.67
Day High
$3.86
Day Low
$3.51
Volume
120.4K
VWAP
$3.73
Prev Close
$3.58
Transactions
--
Acc. Volume
--
About Insight Molecular Diagnostics Inc. Common Stock
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESSIC 283558 employees2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE, TN, 37217949-409-7600IPO Dec 30, 2015US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001642380
- Composite FIGI
- BBG008P5VFV1
- Share Class FIGI
- BBG008P5VFW0
- Ticker Root
- IMDX
- SIC Code
- 2835
About Insight Molecular Diagnostics Inc. Common Stock (IMDX) Stock
Insight Molecular Diagnostics Inc. Common Stock (IMDX) closed the 2026-09-17 session at $3.84, up 7.26% versus the previous close (+0.26). The stock opened at $3.67 and traded between $3.51 and $3.86 during that session. Session trading volume was 120K shares. The volume-weighted average price (VWAP) is $3.73.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Insight Molecular Diagnostics Inc. Common Stock has a market capitalization of $117.2 million. The company operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry classification. IMDX is listed on the XNAS exchange. The company employs approximately 58 people. Insight Molecular Diagnostics Inc. Common Stock is headquartered in NASHVILLE, TN. The recorded listing date is 2015-12-30.
On this page you can find market IMDX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector.